Revolution Medicines faces high volatility after failed Merck takeover talks, with RVMD shares dropping 18% but still up 115% ...

Plotting a challenge to Regeneron’s blockbuster Eylea, Ocular Therapeutix has hired “a key architect” of its rival’s launch ...

RUTLAND — Rutland County Indivisble will hold its International Potluck at 5 p.m. Sunday, Jan. 25, at the Methodist Church, 60 Strongs Ave., Rutland. Bring a family heritage dish or make a new dish ...

At a recent presentation at the Safety Conference in Whistler, Wombat Safety Software emphasized that safety systems ...

Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. Epidemiological evidence indicates that MASLD is associated with an ...

Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA- while at Regeneron Most recently served as Chief Marketin ...

Accomplished global commercial leader with deep expertise in retina drug launchesPrimary architect for the industry-defining launch of EYLEA® ...

A new study published in Therapeutic Innovation & Regulatory Science provides crucial insights into the design and ...

While Fujifilm has deep roots in the life sciences industry through its history working with X-ray film and diagnostic ...

Merck & Co. is buying the developer of an experimental antiviral drug designed to prevent the flu, as the drugmaker aims to counter sales cliffs for two of its biggest drugs. Merck has been vocal ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...